Battle of the Biomarkers of Systemic Inflammation
- PMID: 40282303
- PMCID: PMC12024891
- DOI: 10.3390/biology14040438
Battle of the Biomarkers of Systemic Inflammation
Abstract
Systemic inflammation is monitored with various biomarkers; of these, C-reactive protein (CRP) is widely used due to its cost effectiveness and widespread implementation. However, its lack of specificity and delayed kinetics have directed interest in cell-free DNA (cfDNA), which offers rapid responses to cellular damage. Our review compares the use of CRP and cfDNA in myocardial infarction, sepsis, and physical exercise, focusing on their origins, kinetics, and clinical utility. cfDNA release from apoptotic or damaged cells increases within minutes to hours, providing an early marker of cellular stress. In myocardial infarction, cfDNA peaks early, indicating acute injury, while CRP rises later, reflecting prolonged inflammation. In sepsis, cfDNA correlates strongly with disease severity and prognosis, outperforming CRP in early diagnosis. During physical exercise, cfDNA offers an immediate picture of cellular stress, whereas CRP's delayed response limits its utility in this context. The interaction between CRP and cfDNA suggests their combined application could improve diagnostic accuracy and prognostic assessments. As cfDNA testing becomes more widely available, researchers will need to develop standardized protocols and determine how it can best complement CRP measurements in clinical practice. This approach offers promise for improving the management of systemic inflammation across diverse medical conditions.
Keywords: C-reactive protein (CRP); biomarkers; cell-free DNA (cfDNA); exercise; myocardial infarction; sepsis; systemic inflammation.
Conflict of interest statement
The authors declare no conflicts of interest. The funder had no role in the design of this study, data collection, analysis, decision to publish, or preparation of the manuscript.
Figures



Similar articles
-
Cell Free DNA and Procalcitonin as Early Markers of Complications in ICU Patients with Multiple Trauma and Major Surgery.Clin Lab. 2016 Dec 1;62(12):2395-2404. doi: 10.7754/Clin.Lab.2016.160615. Clin Lab. 2016. PMID: 28164563
-
Circulating cell-free DNA: an up-coming molecular marker in exercise physiology.Sports Med. 2012 Jul 1;42(7):565-86. doi: 10.2165/11631380-000000000-00000. Sports Med. 2012. PMID: 22694348 Review.
-
Cell-free DNA: a metabolic byproduct with diagnostic and prognostic potential in rheumatic disorders.Front Pharmacol. 2025 Feb 11;16:1537934. doi: 10.3389/fphar.2025.1537934. eCollection 2025. Front Pharmacol. 2025. PMID: 40008123 Free PMC article. Review.
-
Early and Late Responses of Cultured Human Mesenchymal Stem Cells (MSCs) to Cell-free DNA (cfDNA) in Patients With Acute Myocardial Infarction.Front Biosci (Landmark Ed). 2025 Mar 31;30(4):28255. doi: 10.31083/FBL28255. Front Biosci (Landmark Ed). 2025. PMID: 40302333
-
Prognostic utility and characterization of cell-free DNA in patients with severe sepsis.Crit Care. 2012 Aug 13;16(4):R151. doi: 10.1186/cc11466. Crit Care. 2012. PMID: 22889177 Free PMC article.
References
-
- Carcò D., Castorina P., Guardo P., Iachelli V., Pace T., Scirè P., Stanco R., Markovic U., Milone G.A., Galbo F., et al. Combination of Interleukin-6, C-Reactive Protein and Procalcitonin Values as Predictive Index of Sepsis in Course of Fever Episode in Adult Haematological Patients: Observational and Statistical Study. J. Clin. Med. 2022;11:6800. doi: 10.3390/jcm11226800. - DOI - PMC - PubMed
-
- Mandel P., Metais P. Nuclear Acids In Human Blood Plasma. C. R. Seances Soc. Biol. Ses. Fil. 1948;142:241–243. - PubMed
Publication types
LinkOut - more resources
Full Text Sources
Research Materials
Miscellaneous